Pliaglis Receives Positive Opinion from the BfArM in the E.U.
News May 08, 2012
Nuvo Research Inc. has announced that it has received notice of a positive opinion from the European Decentralized Procedure for the approval of Pliaglis from the German Federal Institute for Drugs and Medical Devices (BfArM), the reference member state.
The decentralized procedure has been closed with a positive recommendation that Pliaglis is approvable for the indication of producing local dermal anesthesia on intact skin in adults prior to superficial dermatological procedures.
The Marketing Authorization Application (MAA) was submitted by Nuvo to 17 E.U. countries using the decentralized submission procedure to request marketing approval for Pliaglis.
The regulatory process will now enter its final phase known as the national licensing phase.
During this phase, the National Agencies in the individual countries will issue the marketing licenses that allow Pliaglis to be marketed in each country.
Nuvo has licensed worldwide marketing rights for Pliaglis to Galderma S.A. (Galderma), a global pharmaceutical company specialized in dermatology and the individual country licenses will be issued directly to Galderma.
Pursuant to Nuvo's license agreement with Galderma, Nuvo is entitled to receive milestone payments totaling US$6.0 million when certain specified launches occur or within a predefined 6-month period after marketing approval in three different countries.
"We are very pleased that Pliaglis has received a positive recommendation to the MAA supporting its approval in many key European markets," stated Dr. Bradley Galer, President of Nuvo's Pain Group. "This successful result reflects the highly cooperative effort between Nuvo and Galderma."
Researchers Discover Key Link Between Mitochondria and Cocaine AddictionNews
Researchers were able to block response in mitochondria to cocaine.READ MORE
'Click Chemistry' Reactions Could Boost Cancer-Fighting Drug PotencyNews
Researchers at The Scripps Research Institute (TSRI) have developed a quick and easy way to simultaneously modify dozens of drugs or molecules to improve their disease-fighting properties.READ MORE
Novel Green Chemistry Method Improves Pharmaceutical Manufacturing EfficiencyNews
About 70 percent of pharmaceuticals are manufactured using palladium-driven catalytic processes that are either fast or efficient - but not both. Researchers have now developed a green chemistry method that combines aspects of both processes to improve efficiency at a minimal cost of processing time.READ MORE